NEW YORK (GenomeWeb News) – Multiplicom has raised €5.5 million ($7.3 million) to support further development of its molecular diagnostic tests and expansion of its business.

Flemish investment firm PMV, RMM (Rudi Mariën) and Qbic ARKIV Fund were new investors in the round. Existing investors including Belgian venture capital firm Gimv, Gimv-managed Biotechfonds Vlaanderen, and life science research institute VIB continue to support Multiplicom, it said, adding VIB will make an investment in kind.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.